Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
NCT05786521 on ClinicalTrials.gov · last registry update 2025-05-04
A small phase 4 — 20 participants, against a typical 75. The sponsor logged completion for 20 May 2024. Primary outcome, as filed: Lean Body Mass Change. semaglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 20
- Started
- 2023-04-01
- Primary completion
- 2024-05-20 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Lean Body Mass Change
Conditions studied
Aging · Diabetes Mellitus, Type 2 · PreDiabetes · Overweight and Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.